Point72 Asset Management L.P. Raises Stock Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Point72 Asset Management L.P. grew its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 54.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,715,663 shares of the company's stock after acquiring an additional 953,659 shares during the quarter. Point72 Asset Management L.P. owned 2.40% of Centessa Pharmaceuticals worth $43,423,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock valued at $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock worth $48,000 after buying an additional 1,509 shares in the last quarter. Quarry LP raised its position in shares of Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company's stock worth $87,000 after purchasing an additional 3,108 shares during the period. Sandia Investment Management LP acquired a new position in shares of Centessa Pharmaceuticals during the second quarter worth approximately $90,000. Finally, Fred Alger Management LLC acquired a new position in shares of Centessa Pharmaceuticals during the second quarter worth approximately $99,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 16,619 shares of the business's stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $15.69, for a total transaction of $260,752.11. Following the completion of the transaction, the insider now owns 206,750 shares of the company's stock, valued at approximately $3,243,907.50. The trade was a 7.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Saurabh Saha sold 1,671 shares of the business's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $18.24, for a total value of $30,479.04. Following the transaction, the chief executive officer now directly owns 575,661 shares of the company's stock, valued at $10,500,056.64. The trade was a 0.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 375,128 shares of company stock valued at $6,148,522 in the last quarter. 11.59% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock traded up $0.33 during trading hours on Thursday, hitting $17.49. 392,321 shares of the company's stock traded hands, compared to its average volume of 418,173. Centessa Pharmaceuticals plc has a 12-month low of $6.15 and a 12-month high of $18.74. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of -11.43 and a beta of 1.52. The company has a fifty day simple moving average of $16.32 and a 200-day simple moving average of $12.86. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. Equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Morgan Stanley raised Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. B. Riley initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a "buy" rating and a $33.00 price target for the company. Guggenheim increased their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Jefferies Financial Group increased their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Finally, Oppenheimer reissued an "outperform" rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $25.83.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.